Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into how treatment approaches for Hodgkin lymphoma (HL) can be optimized, drawing focus on increasing the number of treatment cycles given to patients, and giving cycles more rapidly. Prof. Nieto also mentions the role of natural killer (NK) cells in the HL treatment landscape, and how these can be combined with other targeted agents to enhance their persistence. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.